Tenax Therapeutics Inc (TENX)
3.10
-0.04
(-1.27%)
USD |
NASDAQ |
Jun 17, 16:00
3.10
0.00 (0.00%)
After-Hours: 20:00
Tenax Therapeutics Free Cash Flow: -9.344M for March 31, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| March 31, 2024 | -9.344M |
| December 31, 2023 | -5.904M |
| September 30, 2023 | -6.418M |
| June 30, 2023 | -7.668M |
| March 31, 2023 | -10.18M |
| December 31, 2022 | -11.39M |
| September 30, 2022 | -12.48M |
| June 30, 2022 | -12.17M |
| March 31, 2022 | -10.58M |
| December 31, 2021 | -10.86M |
| September 30, 2021 | -10.08M |
| June 30, 2021 | -9.441M |
| March 31, 2021 | -9.823M |
| December 31, 2020 | -9.273M |
| September 30, 2020 | -9.012M |
| June 30, 2020 | -8.409M |
| March 31, 2020 | -8.094M |
| December 31, 2019 | -7.560M |
| September 30, 2019 | -7.033M |
| June 30, 2019 | -6.806M |
| March 31, 2019 | -6.082M |
| December 31, 2018 | -5.507M |
| September 30, 2018 | -5.590M |
| June 30, 2018 | -5.261M |
| March 31, 2018 | -9.666M |
| Date | Value |
|---|---|
| December 31, 2017 | -12.15M |
| September 30, 2017 | -13.97M |
| June 30, 2017 | -17.02M |
| March 31, 2017 | -16.59M |
| December 31, 2016 | -15.87M |
| September 30, 2016 | -15.47M |
| June 30, 2016 | -15.05M |
| March 31, 2016 | -11.53M |
| October 31, 2015 | -10.76M |
| September 30, 2015 | |
| July 31, 2015 | -11.32M |
| April 30, 2015 | -10.42M |
| March 31, 2015 | -10.77M |
| January 31, 2015 | -11.23M |
| October 31, 2014 | -10.72M |
| July 31, 2014 | -9.810M |
| April 30, 2014 | -9.409M |
| January 31, 2014 | -7.881M |
| October 31, 2013 | -5.906M |
| July 31, 2013 | -5.023M |
| April 30, 2013 | -5.073M |
| January 31, 2013 | -5.066M |
| October 31, 2012 | -6.611M |
| July 31, 2012 | -8.050M |
| April 30, 2012 | -8.544M |
Free Cash Flow Range, Past 5 Years
-12.48M
Minimum
Sep 2022
-5.904M
Maximum
Dec 2023
-9.126M
Average
-9.309M
Median
Free Cash Flow Benchmarks
| CEL-SCI Corp | -20.40M |
| AIM ImmunoTech Inc | -23.04M |
| IGC Pharma Inc | -6.55M |
| NovaBay Pharmaceuticals Inc | -4.524M |
| Protalix BioTherapeutics Inc | 4.369M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -5.166M |
| Cash from Financing (Quarterly) | 7.923M |
| Free Cash Flow Per Share (Quarterly) | -4.237 |
| Free Cash Flow Yield | -576.1% |